MCID: HML018
MIFTS: 22

Homologous Wasting Disease

Categories: Rare diseases

Aliases & Classifications for Homologous Wasting Disease

MalaCards integrated aliases for Homologous Wasting Disease:

Name: Homologous Wasting Disease 52
Graft-Vs-Host Disease 71

Classifications:



External Ids:

UMLS 71 C0018133

Summaries for Homologous Wasting Disease

MalaCards based summary : Homologous Wasting Disease, is also known as graft-vs-host disease. The drugs Posaconazole and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow.

Related Diseases for Homologous Wasting Disease

Symptoms & Phenotypes for Homologous Wasting Disease

Drugs & Therapeutics for Homologous Wasting Disease

Drugs for Homologous Wasting Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 367)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
2
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
3
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
4
Histamine Approved, Investigational Phase 4 51-45-6 774
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
8
Promethazine Approved, Investigational Phase 4 60-87-7 4927
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
10
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
11
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
12
Povidone Approved Phase 4 9003-39-8
13
Simethicone Approved Phase 4 8050-81-5
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Semustine Experimental, Investigational Phase 4 13909-09-6
16
Treosulfan Investigational Phase 4 299-75-2 9296
17 Antiparasitic Agents Phase 4
18 Antiprotozoal Agents Phase 4
19 Thymoglobulin Phase 4
20 Autonomic Agents Phase 4
21 Adjuvants, Immunologic Phase 4
22
Histamine Phosphate Phase 4 51-74-1 65513
23 Antiemetics Phase 4
24 Gastrointestinal Agents Phase 4
25 Protective Agents Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27 Steroid Synthesis Inhibitors Phase 4
28 Neurotransmitter Agents Phase 4
29 Lubricant Eye Drops Phase 4
30 Anti-Allergic Agents Phase 4
31 Cytochrome P-450 CYP3A Inhibitors Phase 4
32
Hydroxyitraconazole Phase 4
33 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
34 Central Nervous System Depressants Phase 4
35 Hypnotics and Sedatives Phase 4
36 Histamine H1 Antagonists Phase 4
37 Histamine Antagonists Phase 4
38 Anti-Ulcer Agents Phase 4
39 Plasma Substitutes Phase 4
40 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
41 Viscosupplements Phase 4
42 Emollients Phase 4
43 Blood Substitutes Phase 4
44 Antacids Phase 4
45
Budesonide Approved Phase 3 51333-22-3 63006 5281004
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
48
Carmustine Approved, Investigational Phase 2, Phase 3 154-93-8 2578
49
Hydroxychloroquine Approved Phase 3 118-42-3 3652
50
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147

Interventional clinical trials:

(show top 50) (show all 817)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor Completed NCT00044720 Phase 4 Rapamune
3 A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. Completed NCT00195481 Phase 4 Rapamune
4 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
5 A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
6 A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune. Completed NCT00195468 Phase 4 CYCLOSPORINE
7 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
8 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Completed NCT02805946 Phase 4 posaconazole
9 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
10 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients Completed NCT02968134 Phase 4 Posaconazole
11 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
12 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil;Ciclosporin A (CsA);methotrexate (MTX)
13 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
14 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
15 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
16 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
17 The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
18 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
19 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Terminated NCT03490396 Phase 4
20 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
21 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
22 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
23 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Unknown status NCT02291770 Phase 3
24 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
25 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
26 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
27 A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
28 Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD Completed NCT00887263 Phase 3 Budesonide;Placebo
29 An Open-label Extension Study of the Safety of Long-term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients Completed NCT00037531 Phase 3 Sirolimus (RAPAMUNE)
30 Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease Completed NCT00034645 Phase 3 Posaconazole oral suspension
31 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
32 Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3 Budesonide
33 Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
34 A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms Completed NCT00043147 Phase 3 beclomethasone dipropionate;methylprednisolone;prednisone
35 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
36 Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation Completed NCT00001561 Phase 3 Myeloma Immunoglobulin Idiotype Vaccine-KLH;GM-CSF
37 A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Renal Transplant Patients. Completed NCT00167947 Phase 3 Cyclosporine;Steroids;Rapamune (Sirolimus)
38 A Randomized Open-Label Study Comparing the Efficacy and Safety of Sirolimus Combined With Daclizumab, Mycophenolate and Corticosteroids vs Cyclosporine, Mycophenolate and Corticosteroids in Renal Allograft Recipients Receiving Kidneys From Older Donors Completed NCT00195273 Phase 3 sirolimus;cyclosporine;mycophenolate mofetil;corticosteroids;daclizumab
39 A Randomized, Placebo-Controlled, Multi-Center Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal Graft Vs. Host Disease Completed NCT00233896 Phase 3 Oral beclomethasone dipropionate (drug)
40 Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft-vs-Host Disease (aGvHD) Completed NCT02524847 Phase 3 Methoxsalen with ECP
41 Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo Completed NCT00053976 Phase 3 methylprednisolone;Placebo
42 GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S Completed NCT00655343 Phase 3 ATG-Fresenius S
43 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
44 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
45 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
46 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
47 A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal(Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid Refractory Acute GVHD Completed NCT00366145 Phase 3
48 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
49 A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
50 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal

Search NIH Clinical Center for Homologous Wasting Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Daclizumab
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Muromonab-CD3
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Prednisone
PREDNISONE PWDR
Tacrolimus
Thalidomide

Genetic Tests for Homologous Wasting Disease

Anatomical Context for Homologous Wasting Disease

MalaCards organs/tissues related to Homologous Wasting Disease:

40
Bone, T Cells, Bone Marrow, Myeloid, Skin, Eye, Liver

Publications for Homologous Wasting Disease

Articles related to Homologous Wasting Disease:

(show top 50) (show all 2143)
# Title Authors PMID Year
1
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. 61
31804748 2020
2
Are apoptosis-determining-techniques useful to establish an early diagnosis of acute graft vs host disease in pediatric patients under treatment with multiple drugs? 61
32031289 2020
3
The α4β7 blockade with vedolizumab is effective in prevention of graft vs. host disease using a xenogeneic mouse model. 61
31724186 2020
4
Dexamethasone palmitate is a feasible option for the treatment of chronic graft-vs-host disease, particularly with macrophage hyperactivation. 61
31828917 2020
5
Comparison of HLA-matched sibling and unrelated donor transplantation in adult patients with acquired severe aplastic anemia. 61
32024992 2020
6
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report. 61
32035679 2020
7
Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015. 61
30892982 2020
8
Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation: Toxicities with maintenance nivolumab after allogeneic stem cell transplantation. 61
32018063 2020
9
Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. 61
31549435 2020
10
Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogenic hematopoietic stem cell transplantation in children. 61
31951682 2020
11
Killer-cell immunoglobulin-like receptor assessment algorithms in haemopoietic progenitor cell transplantation: current perspectives and future opportunities. 61
31999071 2020
12
Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. 61
31448830 2020
13
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. 61
31913492 2020
14
Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). 61
31625177 2020
15
Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis. 61
31903638 2020
16
Toxoplasma-induced hemophagocytic lymphohistiocytosis after haploidentical allogeneic stem cell transplantation. 61
31895492 2020
17
Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. 61
31849102 2019
18
Apheresis red blood cells associated with repeated hemolysis during blood priming of the Cellex Photopheresis System. 61
31403730 2019
19
Diagnoses of hospitalized patients with skin abnormalities prompting biopsy by consulting dermatologists: A 3-year review from a tertiary care center. 61
31845375 2019
20
The Innate Immune Cell Profile of the Cornea Predicts the Onset of Ocular Surface Inflammatory Disorders. 61
31810226 2019
21
Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients. 61
31893086 2019
22
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. 61
31862477 2019
23
Combination of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation With Unrelated Cord Blood Unit in Patients Aged 35 to 50 Years With Severe Aplastic Anemia: Preliminary Summary of a Single-Arm Trial. 61
31733793 2019
24
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. 61
31830234 2019
25
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. 61
31495933 2019
26
Iron deficiency anemia associated with extracorporeal photopheresis: A retrospective analysis. 61
31436854 2019
27
Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy. 61
31769937 2019
28
Allogeneic Peripheral Blood Stem Cell Transplant: Correlation of Donor Factors with Yield, Engraftment, Chimerism, and Outcome: Retrospective Review of a Single Institute During a 3-Year Period. 61
31758694 2019
29
Yoga for Cancer-Related Fatigue in Survivors of Hematopoietic Cell Transplantation: A Feasibility Study. 61
31765760 2019
30
IFN-γ-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. 61
31401468 2019
31
Adoptive cell therapies for posttransplant infections. 61
31593976 2019
32
Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation. 61
31769584 2019
33
Temporary Cessation of Immunosuppression for Infection May Contribute to the Development of Graft-vs-Host Disease After ABO-Incompatible Living Donor Liver Transplantation: A Case Report. 61
31611115 2019
34
Gastrointestinal Perforations in Adult Whole-Liver Transplant Patients: Clinical, Radiologic, and Histopathologic Analysis. 61
31607622 2019
35
Successful Treatment of Veno-occlusive Disease, Transplantation-Associated Thrombotic Microangiopathy, and Acute Graft-vs-Host Disease in a Patient with Relapsed Epstein-Barr Hemophagocytic Lymphohistiocytosis After Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report. 61
31711585 2019
36
Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. 61
31089279 2019
37
Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience. 61
31502764 2019
38
Successful Salvage Haploidentical Alpha-Beta T Cell-Depleted Stem Cell Transplantation After Busulfan-Based Myeloablation in a Patient With IPEX Syndrome: A Case Report. 61
31611124 2019
39
Melanonychia striata: clarifying behind the Black Curtain. A review on clinical evaluation and management of the 21st century. 61
31006857 2019
40
Establishing a standardized system for review and adjudication of chronic graft-vs-host disease data in accordance with the National Institutes Consensus criteria. 61
31886456 2019
41
Small Opening, Big Problem: Esophageal Food Bolus Impaction and Microstomia. 61
31832452 2019
42
Sudden-Onset Abdominal Pain in a 76-Year-Old Woman With Graft-vs-Host Disease. 61
31590718 2019
43
The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. 61
31162830 2019
44
The utility of cognitive changes in identifying those with acute graft vs. host disease following allogeneic hematopoietic cell transplant. 61
31619131 2019
45
The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. 61
30833743 2019
46
Induction of acute graft vs. host disease in lymphopenic mice. 61
31248669 2019
47
Why, Who, When, and How? Rationale for Considering Allogeneic Stem Cell Transplantation in Children with Sickle Cell Disease. 61
31546720 2019
48
Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. 61
31556923 2019
49
Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI). 61
31558789 2019
50
An automated mini buffy coat preparation method for use in mini extracorporeal photopheresis treatment of graft-vs-host-disease in a low body weight pediatric patient. 61
30829417 2019

Variations for Homologous Wasting Disease

Expression for Homologous Wasting Disease

Search GEO for disease gene expression data for Homologous Wasting Disease.

Pathways for Homologous Wasting Disease

GO Terms for Homologous Wasting Disease

Sources for Homologous Wasting Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....